Brian FinrowPreventive drugs may be the best solution to the antibiotic resistance crisisBy Brian Finrow│This piece was originally published at STAT NEWS on October 18, 20238 min read·Nov 9, 2023----
Brian FinrowCOVID drugs come in 3 flavors; it’s time for more diversityBy Brian Finrow │This piece was originally published at Drug Discovery & Development on October 12th, 20216 min read·Mar 23, 2023----
Brian FinrowDrug developers navigating ‘biology’s century’ need a model. We made oneBy Brian Finrow, Aleks Engel and Srinivas Akkaraju │This piece was originally published at STAT NEWS on March 15th, 202310 min read·Mar 20, 2023----
Brian FinrowMoving closer to the patientThoughts on the journey from bench to bedside for patients at risk of C. difficile infection6 min read·Apr 18, 2022----
Brian Finrow‘You can’t get there from here:’ Birth of a biotech platformLumen’s new paper in Nature Biotechnology describes how it harnessed spirulina as a factory and delivery vehicle for oral protein…6 min read·Mar 23, 2022----
Brian FinrowIntranasal passive vaccines: thinking beyond the jabThoughts on Lumen’s new collaboration to fight flu with inhaled antibodies6 min read·Feb 1, 2022----
Brian FinrowAntibody synergyA new tool for making high-potency antibody drugs16 min read·Dec 24, 2021----
Brian FinrowCovid therapies must look beyond the lungsThe “respiratory” disease strikes many organ systems, including the GI tract. Lumen is testing the world’s first oral therapy directed at…12 min read·Oct 6, 2021----
Brian FinrowMachine learning meets molecular farmingHow Google’s AI experts are helping advance Lumen Bio’s unique biologics platform6 min read·Aug 11, 2021----
Brian FinrowThe ideal platform to fight a silent pandemicReflecting on Lumen’s new collaboration with Novo Nordisk4 min read·Jun 16, 2021----
